ÂÜÀòÂÒÂ×

Daniel Leutenegger is a seasoned professional in the pharmaceutical and life sciences sectors, currently serving as Director, Patient Value Lead in Neuroscience at Takeda since April 2020, where responsibilities include driving diagnosis and patient solution strategies. Prior experience at PwC from April 2016 to March 2020 includes roles as Senior Manager and Associate Director, focusing on strategy and transformation initiatives. Key projects during this time involved establishing a Medical Research Center for Precision Medicine and advising health authorities on biomedical research. Daniel co-founded Stemergie Biotechnology SA, a company dedicated to developing cancer treatments, and has held various consulting and management roles across prominent firms. Daniel holds an MBA from IMD and a B.A. in Business Administration from the University of St.Gallen.